Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCQ908 Extension in Familial Chylomicronemia Syndrome
NCT01589237Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of pradigastat in familial chylomicronemia syndrome (FCS), sponsored by Novartis. Started Feb 2013; status: terminated.
02
Drugs
pradigastat
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT01589237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01589237.